Top Markets
#1 Akedo Akedo +146.29%
#2 TENDIES TENDIES +96.27%
#3 Threshold Network Threshold Network +47.05%
#4 Verus Coin Verus Coin +43.84%
#5 Mubarak Mubarak +27.69%
#6 Bitway Bitway +26.92%
#7 MultiversX MultiversX +23.94%
#8 Palladium Network Palladium Network +22.69%
#9 Cash Cat Cash Cat +22.59%
#10 aelf aelf +19.17%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Shukra Pharmaceuticals Limited Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited

SHUKRAPHAR
Rank in Stocks #17792
Shukra Pharmaceuticals Limited is a prominent company engaged in the... Shukra Pharmaceuticals Limited is a prominent company engaged in the manufacturing and global distribution of pharmaceutical products. Their comprehensive product line addresses a broad spectrum of medical conditions, encompassing anti-infective medications (such as antibiotics, macrolides, quinolones, antivirals, antifungals, antimalarials, antiprotozoals, and anti-helminthics), central nervous system drugs (including sedatives, tranquilizers, antidepressants, and anti-manic agents), gastrointestinal treatments (like anti-emetics and anti-ulcer drugs), cardiovascular remedies (beta-blockers, diuretics), pain and inflammation management (analgesics, muscle relaxants, corticosteroids), anti-tuberculosis drugs, vitamin supplements, anti-allergy medications, and therapies for metabolic imbalances such as hyper- and hypoglycemia. The company was established on March 4, 1993, and its primary operations are directed from its headquarters in Ahmedabad, India.
Share Price
$0.51647906
Market Cap
$226.16M
Change (1 day)
5.29%
Change (1 year)
66.66%
Country
IN
Trade Shukra Pharmaceuticals Limited (SHUKRAPHAR)

Category

Healthcare
P/E ratio for Shukra Pharmaceuticals Limited (SHUKRAPHAR)
P/E ratio as of 2026 TTM: 0
According to Shukra Pharmaceuticals Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Shukra Pharmaceuticals Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 25.48 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 34.09 -
HK
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.